Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064220 · ClinicalTrials.gov registry record · Phase 2
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00064220 is a Phase 2 study that has completed, run by Daiichi Sankyo.
The verdict
NCT00064220, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of soblidotin in treating patients who have advanced or metastatic soft tissue sarcoma.
Interventions
- DRUG soblidotin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-04 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064220
The ClinicalTrials.gov registry entry for NCT00064220 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which soblidotin is the first listed.
NCT00064220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00064220 about?
NCT00064220 is a clinical study titled "Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma". RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of soblidotin in treating patients who have advanced or metastatic soft tissue sarcoma.
What is the current status of trial NCT00064220?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-04. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00064220?
The interventions under investigation include: soblidotin (DRUG).
Who is sponsoring clinical trial NCT00064220?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.